

**Supplementary Table 1.** Summary of reported cases of MOGAD associated with anti-TNF therapy

No.	Age/sex	Primary disease	Anti-TNF agent at symptom onset	Duration of anti-TNF therapy, before symptom onset	MOGAD Presentation	Treatment	Ref
1	28/M	Crohn's disease	Infliximab	2 years	Cortical encephalitis	IVMP	Present case
2	64/M	Ankylosing spondylitis	Adalimumab (stopped)	15 years, 1 month after discontinuation	Brainstem syndrome	IVMP	Baddamet et al. <sup>1</sup> (2025)
3	26/F <sup>a</sup>	Ankylosing spondylitis	Etanercept (stopped)	10 weeks, 2 years after discontinuation	Concurrent ON and LETM	IVMP, MMF	Luo et al. <sup>2</sup> (2021)
4	17/M	Psoriasis	Adalimumab	2 years	Cortical encephalitis	IVMP, IVIG	Deniz and Sönmez <sup>3</sup> (2025)
5	49/M	Psoriatic arthritis	Adalimumab (prior etanercept)	12 years (prior etanercept for 10 years)	Brainstem syndrome with headache	Oral dexamethasone	Redenbaugh et al. <sup>5</sup> (2022)
6	40/M	Pustular psoriasis	Adalimumab (prior etanercept)	18 months (prior etanercept for 15 months)	LETM onset followed by ON	IVMP, MMF <sup>b</sup>	Lommers et al. <sup>4</sup> (2018)
7	42/M	Inflammatory arthritis	Etanercept	2 years	Bilateral ON	IVMP, tocilizumab	Redenbaugh et al. <sup>5</sup> (2022)
8	34/M	Ulcerative colitis	Infliximab	10 years	Cortical encephalitis	IVMP	Chang et al. <sup>6</sup> (2021)
9	36/F	Crohn's disease, HLA-B27 positive spondyloarthropathy, hidradenitis suppurativa	Adalimumab	Unspecified	Cortical encephalitis	IVMP, levetiracetam	Cabezudo-García et al. <sup>7</sup> (2022)

MOGAD, myelin oligodendrocyte glycoprotein-associated disease; TNF, tumor necrosis factor; Ref, reference; M, male; IVMP, intravenous methylprednisolone; F, female; ON, optic neuritis; LETM, longitudinally extensive transverse myelitis; MMF, mycophenolate mofetil; IVIG, intravenous immunoglobulin; HLA-B27, human leukocyte antigen-B27.

<sup>a</sup>Postpartum.

<sup>b</sup>After optic neuritis relapse.

## I Supplementary Table REFERENCES

1. Baddam S, Patel S, Kahlon N, Thiriveedi M. Unmasking myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): CNS demyelination triggered by TNF- $\alpha$  inhibition in a patient with ankylosing spondylitis. *Eur J Case Rep Intern Med* 2025;12:005467.
2. Luo W, Li R, Chang Y, She H, Kermode AG, Qiu W. Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: potential association between demyelination and tumor necrosis factor inhibitors. *Mult Scler Relat Disord* 2021;51:102889.
3. Deniz A, Sönmez HE. Exploring the paradox: the role of TNF- $\alpha$  inhibitors in the emergence of FLAIR-hyperintense lesions and seizures in anti-MOG encephalitis - a case-based review. *J Child Neurol* 2025:8830738251401035.
4. Lommers E, Depierreux F, Hansen I, Dive D, Maquet P. NMOSD with anti-MOG antibodies following anti-TNF $\alpha$  therapy: a case report. *Mult Scler Relat Disord* 2018;26:37-39.
5. Redenbaugh V, Flanagan EP, Floris V, Zara P, Bhatti MT, Sanchez F, et al. Exposure to TNF inhibitors is rare at MOGAD presentation. *J Neurol Sci* 2022;432:120044.
6. Chang YC, Sharma M, Budhram A. Unilateral cortical FLAIR-hyperintense lesion in anti-MOG-associated encephalitis with seizures (FLAMES) on TNF inhibitor therapy. *J Neurol Neurosurg Psychiatry* 2021;jnnp-2021-326401.
7. Cabezudo-García P, Denis MV, Ciano-Petersen NL, Irigoyen-Oyarzábal MV, Serrano-Castro PJ. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment. *Neurologia* 2022;37:304-306.